CTOs on the Move

Vault Health

www.vaulthealth.com

 
The Vault Health platform provides a robust and flexible technology stack at the foundation of a multimodal healthcare service ecosystem. The platform features a powerful suite of digital healthcare tools designed to tackle a broad scope of modern medical use cases, including individual care, population health, and clinical trials. The Vault digital healthcare toolkit includes on-demand telehealth consultations and sample supervision, patient and provider communications, in-person and remote appointment management, longitudinal care management, and beyond. Vault gravitates to opportunities and partnerships that empower them to share and expand their platform`s capabilities and impact.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.vaulthealth.com
  • 133 East 58th Street Suite 512
    New York, NY USA 10022
  • Phone: 212.880.5494

Executives

Name Title Contact Details
Steven Shi
Chief Technology Officer Profile

Funding

Vault Health raised $30M on 03/12/2020

Similar Companies

Electromed Co

Electromed Co is a City Of Industry, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

fitness marketing systems

fitness marketing systems is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clearway Health

Clearway Health partners with hospitals and health systems to build or strengthen their own specialty pharmacy program, improve access to care and provide personalized support to vulnerable patients, families, providers and care managers to eliminate b...

Murphy Medical Center

Murphy Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Murphy Medical Center is based in Murphy, NC. You can find more information on Murphy Medical Center at www.murphymedical.org

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.